Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys

Fuwa M., Shimazaki A., Odani-Kawabata N., Kirihara T., Taniguchi T., Iwamura R., Yoneda K., Kato M., Morishima K., Shams N.K.

2021
Journal of Ocular Pharmacology and Therapeutics

View publication

Therapeutic Area

Glaucoma
Categories

Preclinical development

Affiliations

Fuwa, M., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Shimazaki, A., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Odani-Kawabata, N., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan, Product Development Division, Santen Inc., Emeryville, CA, United States; Kirihara, T., Ophthalmology Innovation Center, Santen Pharmaceutical Co. Ltd., Osaka, Japan; Taniguchi, T., Ophthalmology Innovation Center, Santen Pharmaceutical Co. Ltd., Osaka, Japan; Iwamura, R., Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; Yoneda, K., Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; Kato, M., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Morishima, K., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Shams, N.K., Product Development Division, Santen Inc., Emeryville, CA, United States, Ophthalmology Innovation Center, Santen Inc., Emeryville, CA, United States

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.